CandyT.A., SchneiderP.J., PedersonC.A.Impact of the United States Pharmacopeia chapter 797: results of a national survey. Am J Health-Syst Pharm.2006; 63: 1336–1343.
2.
FrickerM.P., TrisselL.A., RichD.S.Turning a new chapter on IV drug compounding safety: USP/NF Chapter <797>. Hosp Pharm.2004; 39: 899–920.
3.
KopchaR.G.Lack of evidence for ASHP's sterile-products guidelines. Am J Health-Syst Pharm.2004; 61: 1445–1446.
4.
ThompsonC.A.USP Chapter 797 enforceable but not often enforced. Am J Health-Syst Pharm.2006; 63: 988–990.
5.
ThomasM., SanbornM.D., CouldryR.I.V. admixture contamination rates: Traditional practice site versus a class 1000 cleanroom. Am J Health-Syst Pharm.2005; 62: 2386–2392.
6.
TrisselL.A., GentempoR.W., AndersonR.W., LajeunesseJ.D.Using a medium-fill simulation to evaluate the microbial contamination rate for USP medium-risk-level compounding. Am J Health-Syst Pharm.2005; 62: 285–8.
7.
TrisselL.A., OgundeleA.B., IngramD.S., SaenzC.A., GentempoJ.A.Using medium-fill simulation to establish a benchmark microbiological contamination rate for low-risk-level compounding. Am J Health-Syst Pharm.2003; 60: 1853–5.
8.
TrapskinP.J., ReaganR., HiteK., ArmitsteadJ.A.The implementation of a personnel training and assessment program for new standards in the US pharmacopeia general chapter <797> pharmaceutical compounding of sterile products. Hosp Pharm.2006; 41: 43–48.
